Cantor Fitzgerald Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

Key Points

• Cantor Fitzgerald has raised its target price for United Therapeutics (NASDAQ: UTHR) stock from $405.00 to $525.00, indicating a potential upside of 30.77% from the current price.
• Multiple research firms have issued favorable ratings for United Therapeutics, with nine analysts rating it as a Buy and an average target price of $438.85.
• Insider selling has been notable, with executives recently disposing of a combined total of 106,181 shares in the past 90 days, suggesting caution among company insiders.

United Therapeutics (NASDAQ:UTHR - Get Free Report) had its target price raised by analysts at Cantor Fitzgerald from $405.00 to $525.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the biotechnology company's stock. Cantor Fitzgerald's price objective indicates a potential upside of 30.77% from the company's current price.

A number of other research firms also recently issued reports on UTHR. HC Wainwright increased their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a research report on Friday, September 5th. Jefferies Financial Group increased their price target on shares of United Therapeutics from $432.00 to $564.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Bank of America raised their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Finally, UBS Group raised their price objective on shares of United Therapeutics from $415.00 to $560.00 and gave the company a "buy" rating in a research report on Thursday, September 4th. Nine analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $438.85.

United Therapeutics Stock Down 0.6%

Shares of NASDAQ:UTHR opened at $401.45 on Wednesday. United Therapeutics has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The company has a market cap of $18.11 billion, a PE ratio of 15.72, a P/E/G ratio of 6.02 and a beta of 0.62. The firm has a 50-day simple moving average of $312.09 and a 200 day simple moving average of $306.29.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. During the same quarter last year, the business earned $5.85 earnings per share. The company's revenue was up 11.7% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Activity

In related news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $385.21, for a total value of $4,237,310.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company's stock, valued at approximately $14,168,409.01. This trade represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Insiders have sold a total of 106,181 shares of company stock worth $35,537,239 in the last 90 days. 10.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Chung Wu Investment Group LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at about $29,000. SVB Wealth LLC purchased a new stake in shares of United Therapeutics in the 1st quarter worth $32,000. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after buying an additional 46 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 85 shares during the period. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.